CDKN2A and B-cell non-Hodgkin lymphoma: Eμ-Myc: HPCs with vector; pre-B-cell lymphomas with 20% incidence at 14 weeksEμ-Myc; Arf
−/− tumors responded to doxorubicin or rapamycin but responded to the combination